BeOne Medicines Ag logo

BeOne Medicines Ag(SEHK) 6160

Market CapHK$307.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+100%
5 Year-2%
1 Year+13%
1 Month-2%
HK$214.40
+2.39%
+5.00Today
BeOne Medicines Ag last closing stock price
MetricPriceDate
Last closeHKD 209.402026-10-14
BeOne Medicines Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.5%HKD 217.002026-10-07
1 month-1.6%HKD 212.802026-09-14
3 month+9.75%HKD 190.802026-07-16
Year to date+16.79%HKD 179.302025-12-31
1 year+12.7%HKD 185.802025-10-14
3 year+94.79%HKD 107.502023-10-13
5 year-1.97%HKD 213.602021-10-15
Since inception+100.37%HKD 107.002018-08-08

BeOne Medicines Ag Financials at a Glance

Market Cap

HK$307.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.12B

Net Income (TTM)

$654.97M

EPS (TTM)

HK$3.41

P/E Ratio

61.32

Dividend

HK$0.00

Beta (Volatility)

0.16 (Low)

Price

HK$214.40

Volume

2,053,479

Open

HK$213.00

Previous Close

HK$209.40

Daily Range

HK$211.80 - HK$218.80

52-Week Range

HK$153.00 - HK$235.60

Estimated Earnings Date

Nov 5, 2026

6160 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BeOne Medicines Ag

BeOne Medicines AG is a global oncology company based in Switzerland, focused on developing innovative and affordable cancer treatments. The company is dedicated to enhancing accessibility for cancer patients worldwide through a diverse pipeline of novel therapeutics.

Products and Services
  • Innovative oncology treatments targeting hematology and solid tumors
  • Collaborative development efforts to expedite therapeutic advancements
  • Focus on affordability and accessibility for cancer patients
Growth Outlook
  • Recent quarterly revenue reached USD 1.71 billion, reflecting strong market demand
  • Trailing twelve months (TTM) gross profit margin stands at 87.8%, indicating operational efficiency
  • Significant cash reserves of USD 5.1 billion support ongoing research and development
Financial Highlights
  • Net income for Q2 2026 was USD 237 million, showcasing robust profitability
  • Operating income margin of 19.1% in Q2 2026 highlights effective cost management
  • Current ratio of 3.40 indicates strong liquidity position for future investments
AI Generated • Oct 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

12,000

CEO

John V. Oyler, MBA

Website

beonemedicines.com

Headquarters

Basel, BL 4051, CH

6160 Financials

Key Financial Metrics (TTM)

Gross Margin

87.82%

Operating Margin

15.06%

Net Income Margin

10.70%

Return on Equity

14.22%

Return on Capital

8.21%

Return on Assets

7.14%

Earnings Yield

1.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$307.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.47B

Volume

2.05M

Avg. Volume

3.89M

Financials (TTM)

Gross Profit

$5.38B

Operating Income

$922.19M

EBITDA

$1.10B

Operating Cash Flow

$1.49B

Capital Expenditure

-$175.33M

Free Cash Flow

$1.31B

Cash & ST Invst.

$5.10B

Total Debt

$1.14B

BeOne Medicines Ag Performance Analysis

BeOne Medicines Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 11,087,354,02421.3%
20232023-12-31USD 19,249,639,19673.6%
20242024-12-31USD 29,731,162,67454.5%
20252025-12-31USD 41,654,498,57540.1%
BeOne Medicines Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.4%
Q42025-12-316.0%
Q12026-03-310.8%
Q22026-06-3013.0%
BeOne Medicines Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -11.7024.6%
20232023-12-31USD -5.09-56.5%
20242024-12-31USD -3.68-27.7%
20252025-12-31USD 1.52N/A
BeOne Medicines Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3042.2%
Q42025-12-31-48.8%
Q12026-03-31243.2%
Q22026-06-306.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.71B

+29.6%

Gross Profit

$1.53B

+33.0%

Gross Margin

89.76%

N/A

Market Cap

HK$307.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$25.66M

N/A

Employees

12,000

N/A

Net Income

$237.01M

+151.3%

EBITDA

$392.71M

+218.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.10B

+85.0%

Total Debt

$1.14B

+11.5%

Accounts Receivable

$1.07B

+21.7%

Inventory

$732.60M

+45.7%

Long Term Debt

$930.36M

+365.1%

Short Term Debt

$212.85M

-74.2%

Return on Assets

7.14%

N/A

Return on Invested Capital

13.07%

N/A

Free Cash Flow

$414.83M

+107.6%

Operating Cash Flow

$462.82M

+75.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About 6160

What is the current price of BeOne Medicines Ag?

BeOne Medicines Ag is trading at HK$214.40 per share.

What is the 52-week range for BeOne Medicines Ag?

Over the past 52 weeks, BeOne Medicines Ag has traded between HK$153.00 and HK$235.60.

How much debt does BeOne Medicines Ag have?

As of the most recent reporting period, BeOne Medicines Ag reported total debt of $16.07B.

How much cash does BeOne Medicines Ag have on hand?

BeOne Medicines Ag reported $41.24B in cash and cash equivalents in its most recent financial results.

What is BeOne Medicines Ag’s dividend yield?

BeOne Medicines Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services